Mitomycin nephrotoxicity

Mitomycin C -antitumor antibiotic inhibits RNAand DNA synthesis -bone marrow suppression -nausea and vomiting—mild to moderate -mucocutaneous effects (mucositis, stomatitis, diarrhea) -vesicant if extravasated -nephrotoxicity -veno-occlusive disease (VOD) of the liver -hemolytic-uremic syndrome... 

Mitomycin Mutamycin Carcinoma of stomach and pancreas chronic myelocytic leukemia Blood disorders [leukopenia, thrombocytopenia] Gl distress [nausea, vomiting, Gl irritation and ulceration] nephrotoxicity pulmonary toxicity... 

Increased risk of nephrotoxicity with acyclovir, aminoglycoside, cyclosporine, flucytosine, foscamet, gancyclovrr, mitomycin, penicillamine, sirolimus, vancomycin... 

Antibiotics The clinical use of three antibiotic cancer chemotherapeutic drugs (mitomycin C, mi-thramycin, and doxorubicin) has been associated with the development of nephrotoxicity. Each of these drugs is commonly used in combination chemotherapy which in some cases might result in additive or enhanced nephrotoxicity. 

Mitomycin C is isolated from Streptomyces ca-espitosis and is used in the treatment of solid tumors. Renal failure (elevated BUN and serum creatinine concentration, proteinuria) induced by mitomycin C is dose dependent and cumulative. When administered alone, the incidence of nephrotoxicity is less than 1%, but in combination with 5-fluorouracil nephrotoxicity occurs more frequently and can be marked. The chemical species responsible for mitomycin C nephrotoxicity appears to result from the formation of alkylating metabolites. 

Mitomycin C is a carcinogen (sarcomas and other cancers) in mice and rats after intraperitoneal, intravenous, or subcutaneous injections. It is teratogenic in mice (including skeletal defects). It is nephrotoxic. It is mutagenic in sister chromatid exchange assays. 

---